Pancreatic Cancer Research

ResearcherCatholic University of KoreaActive in the last 2 years

In Seok Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1127-1522; OpenAlex author ID A5058738526. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 9

  1. Characteristics of Early Pancreatic Cancer: Comparison between Stage 1A and Stage 1B Pancreatic Cancer in Multicenter Clinical Data Warehouse Study. Co-author DOI 10.3390/cancers16050944↗
  2. Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. Co-author DOI 10.3390/biomedicines10061289↗
  3. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observat… Co-author DOI 10.1186/s12885-020-07753-w↗
  4. Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. Co-author DOI 10.1371/journal.pone.0240318↗
  5. [Development of a Pancreatic Cancer Specific Binding Peptide Using Phage Display]. Co-author DOI 10.4166/kjg.2019.74.1.30↗
  6. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. Co-author DOI 10.1002/jcsm.12274↗
  7. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? Co-author DOI 10.1016/j.ejca.2018.08.027↗
  8. [Does Preoperative Drainage of Metal Stent Decrease Operation Related Complication in Resectable Pancreatic Cancer?]. First author DOI 10.4166/kjg.2015.66.6.363↗
  9. Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Co-author DOI 10.1007/s00432-012-1234-y↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Myung Ah Lee · 6 shared papers, 2012–2022 · strength 0.66
  2. Tae Ho Hong · 6 shared papers, 2012–2022 · strength 0.66
  3. Moon Hyung Choi · 5 shared papers, 2018–2022 · strength 0.63
  4. Seung Bae Yoon · 4 shared papers, 2018–2022 · strength 0.46
  5. Eun Sun Jung · 3 shared papers, 2018–2022 · strength 0.37
  6. Young Hoon Choi · 2 shared papers, 2022–2024 · strength 0.36
  7. Meiying Song · 3 shared papers, 2018–2020 · strength 0.29
  8. Ho Joong Choi · 2 shared papers, 2018–2022 · strength 0.25
  9. Hyo Suk Kim · 1 shared paper, 2024 · strength 0.20
  10. Sung Woo Ko · 1 shared paper, 2024 · strength 0.20
  11. Jae Hyuck Chang · 1 shared paper, 2024 · strength 0.20
  12. Myung‐Gyu Choi · 2 shared papers, 2018–2019 · strength 0.19
  13. In-Ho Kim · 1 shared paper, 2021 · strength 0.17
  14. Yoon Jin Roh · 1 shared paper, 2019 · strength 0.11
  15. Dong Won Lee · 1 shared paper, 2019 · strength 0.11
  16. Seung Eun Ha · 1 shared paper, 2015 · strength 0.11
  17. Myung‐Gyu Choi · 1 shared paper, 2018 · strength 0.09
  18. Eun Kyoung Jeon · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.